Arrowhead Pharmaceuticals, Inc.
ARWR
$65.09
$0.020.02%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 823.66% | -94.88% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 823.66% | -94.88% | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | 823.66% | -94.88% | |||
| SG&A Expenses | -16.34% | 3.64% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 9.85% | 19.70% | |||
| Operating Income | 126.64% | -143.43% | |||
| Income Before Tax | 120.17% | -148.45% | |||
| Income Tax Expenses | 4,676.66% | -124.93% | |||
| Earnings from Continuing Operations | 109.02% | -148.56% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -1,268.89% | 32.11% | |||
| Net Income | 86.45% | -147.31% | |||
| EBIT | 126.64% | -143.43% | |||
| EBITDA | 131.69% | -141.14% | |||
| EPS Basic | 86.33% | -145.38% | |||
| Normalized Basic EPS | 83.93% | -144.56% | |||
| EPS Diluted | 86.19% | -145.83% | |||
| Normalized Diluted EPS | 83.93% | -144.93% | |||
| Average Basic Shares Outstanding | -0.84% | 4.26% | |||
| Average Diluted Shares Outstanding | -0.84% | 3.39% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||